Funding options, page-14

Seemed most relevant here...don't shoot the messenger.

An insider, the founder of SurgCenter, essentially a vast day hospital network in the US, has just bought 10,000,000 shares in MSB.

Now I apologise to those who hate MSB discussions to PAR, but there is relevance.

SurgCenter is a massive ambulatory network with orthopedic specialisation; "performed over 4100 Total Joint Replacements, more than any other outpatient surgery center in the United States". If they are looking at MSB, there is no way they, and others, will be unaware of PAR's Zilosul injectable Pentosan Polysulfate Sodium (iPPS) treatment of symptomatic osteoarthritis, the bread and butter of its patients presentations.

A massive outpatient network that could so easily apply an injectable in its business. WIth PAR's NFL affiliations, there is no way SurgCenter and others are unaware of PAR. WHilst many PAR owners will probably dislike the cross discussion, its relevant. If US big Pharma is buying into MSB, its not going to be unaware of PAR.....

A potential source of funding, or even predatory take over at these cheap prices....